OPT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 16:00):

Stats
Today's Volume	1 881.00
Average Volume	19 745.00
Market Cap	275.07M
EPS	$0 ( 2023-09-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.380
ATR14	$0.0330 (0.99%)

Insider Trading

Date	Person	Action	Amount	type
2006-03-06	Harrold Jason M	Sell	7 000	Employee Stock Option (right to buy)
2006-03-06	Harrold Jason M	Sell	22 500	Employee Stock Option (right to buy)
2006-03-06	Harrold Jason M	Sell	15 000	Common Stock, $.001 par value per share
2006-03-06	Harrold Jason M	Sell	25 000	Employee Stock Option (right to buy)
2006-03-06	Harrold Jason M	Sell	125 000	Employee Stock Option (right to buy)

INSIDER POWER
0.00
Last 21 transactions
Buy: 142 000 \| Sell: 593 104

Opthea Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Opthea Limited Financials

Annual	2023
Revenue:	$108 406
Gross Profit:	$-142 066 (-131.05 %)
EPS:	$-2.43

FY	2023
Revenue:	$108 406
Gross Profit:	$-142 066 (-131.05 %)
EPS:	$-2.43

FY	2022
Revenue:	$90 683.00
Gross Profit:	$-141 786 (-156.35 %)
EPS:	$-1.990

FY	2021
Revenue:	$68 613.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.132

Financial Reports:

No articles found.

Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.